Keywords: bayhill, doses, ph, ii, ms, trial, raises

Bayhill doses in Ph II MS trial, raises $15.8M

Article | 17 April 2006

Print This

California, USA-based Bayhill Therapeutics says it has begun dosing patients with BHT-3009, its experimental drug candidate, in a Phase II ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in